View in EDS

The role of RAD23A in DNA repair and proteasome-dependent protein degradation in multiple myeloma.

Saved in:
Bibliographic Details
Title: The role of RAD23A in DNA repair and proteasome-dependent protein degradation in multiple myeloma.
Authors: Wan X; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Du T; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Fang T; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Wang M; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Ray A; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Wen K; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Musa MA; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Garbicz F; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Carrasco RD; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Samur AA; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Fulciniti M; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Talluri S; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Song Y; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. yan_song@dfci.harvard.edu., Munshi NC; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Nikhil_munshi@dfci.harvard.edu.; VA Boston Healthcare System, Boston, MA, USA. Nikhil_munshi@dfci.harvard.edu., Anderson KC; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. kenneth_anderson@dfci.harvard.edu.
Source: Blood cancer journal [Blood Cancer J] 2026 Jul 15. Date of Electronic Publication: 2026 Jul 15.
Publication Type: Journal Article
Journal Info: Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42457667
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: The role of RAD23A in DNA repair and proteasome-dependent protein degradation in multiple myeloma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Wan+X%22">Wan X</searchLink>; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Du+T%22">Du T</searchLink>; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Fang+T%22">Fang T</searchLink>; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Wang+M%22">Wang M</searchLink>; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Ray+A%22">Ray A</searchLink>; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Wen+K%22">Wen K</searchLink>; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Musa+MA%22">Musa MA</searchLink>; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Garbicz+F%22">Garbicz F</searchLink>; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Carrasco+RD%22">Carrasco RD</searchLink>; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Samur+AA%22">Samur AA</searchLink>; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Fulciniti+M%22">Fulciniti M</searchLink>; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Talluri+S%22">Talluri S</searchLink>; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Song+Y%22">Song Y</searchLink>; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. yan_song@dfci.harvard.edu.<br /><searchLink fieldCode="AU" term="%22Munshi+NC%22">Munshi NC</searchLink>; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Nikhil_munshi@dfci.harvard.edu.; VA Boston Healthcare System, Boston, MA, USA. Nikhil_munshi@dfci.harvard.edu.<br /><searchLink fieldCode="AU" term="%22Anderson+KC%22">Anderson KC</searchLink>; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. kenneth_anderson@dfci.harvard.edu.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101568469%22">Blood cancer journal</searchLink> [Blood Cancer J] 2026 Jul 15. <i>Date of Electronic Publication: </i>2026 Jul 15.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Pub%2E+Group%22">Nature Pub. Group </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101568469 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2044-5385 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220445385%22">20445385 </searchLink><i>NLM ISO Abbreviation: </i>Blood Cancer J <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42457667
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41408-026-01574-z
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: The role of RAD23A in DNA repair and proteasome-dependent protein degradation in multiple myeloma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Wan X
      – PersonEntity:
          Name:
            NameFull: Du T
      – PersonEntity:
          Name:
            NameFull: Fang T
      – PersonEntity:
          Name:
            NameFull: Wang M
      – PersonEntity:
          Name:
            NameFull: Ray A
      – PersonEntity:
          Name:
            NameFull: Wen K
      – PersonEntity:
          Name:
            NameFull: Musa MA
      – PersonEntity:
          Name:
            NameFull: Garbicz F
      – PersonEntity:
          Name:
            NameFull: Carrasco RD
      – PersonEntity:
          Name:
            NameFull: Samur AA
      – PersonEntity:
          Name:
            NameFull: Fulciniti M
      – PersonEntity:
          Name:
            NameFull: Talluri S
      – PersonEntity:
          Name:
            NameFull: Song Y
      – PersonEntity:
          Name:
            NameFull: Munshi NC
      – PersonEntity:
          Name:
            NameFull: Anderson KC
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 15
              M: 07
              Text: 2026 Jul 15
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 2044-5385
          Titles:
            – TitleFull: Blood cancer journal
              Type: main
ResultId 1